Anne Wojcicki, co-founder of 23andMe, is reclaiming the company through her new nonprofit TTAM Research Institute, which has agreed to acquire nearly all of 23andMe’s assets for $305 million. The deal, which includes its DNA testing business and telehealth unit Lemonaid Health, outbids Regeneron’s earlier $256 million offer and is pending court approval. 23andMe filed for Chapter 11 in March after privacy breaches and business struggles, falling far from its $6 billion peak valuation. Wojcicki says the move will allow TTAM to continue 23andMe’s original mission.
